TY - JOUR
T1 - Current evidence on the adoption of indicator condition guided testing for HIV in western countries: A systematic review and meta-analysis
AU - Bogers, S. J.
AU - Hulstein, S. H.
AU - Schim van der Loeff, M. F.
AU - de Bree, G. J.
AU - Reiss, P.
AU - HIV Transmission Elimination AMsterdam (H-TEAM) Consortium
AU - van Bergen, J. E. A. M.
AU - Geerlings, S. E.
N1 - Funding Information: The H-TEAM initiative, of which this review is a project, is being supported by Aidsfonds (Grant No. 2013169), Stichting Amsterdam Dinner Foundation, Bristol-Myers Squibb International Corp. (study number: AI424?541), Gilead Sciences Europe Ltd (Grant No. PA-HIV-PREP-16-0024), Gilead Sciences (protocol numbers: CO-NL-276-4222, CO-US-276-1712), Janssen Pharmaceutica (reference number: PHNL/JAN/0714/0005b/1912fde), M.A.C AIDS Fund, ViiV Healthcare (PO numbers: 3000268822, 3000747780) and ZonMw (Grant No. 522002003). This review is further funded by Aidsfonds (Grant No. P- 42702). The funders of the study had no role in the study design or execution. Funding Information: Dr. Bogers reports grants from Aidsfonds, grants from H-TEAM, during the conduct of the study; and this work is partially funded by H-TEAM, a consortium of all actors involved in hiv-care and prevention in Amsterdam, with the ultimate goal to pursue the end of new hiv-infections in Amsterdam. The H- team is sponsored by a mix of organisations, including the Municipality, AIDS-funds, and several farmaceutical companies ( www.hteam.nl ). There are no personal fees or payment involved. H-TEAM is not involved in the design or conduct of this work. S.H.H. Hulstein has nothing to disclose. Dr. Schim van der Loeff reports other from Merck, non-financial support from Stichting Pathologie Onderzoek en Ontwikkeling (SPOO), outside the submitted work. Dr. de Bree reports grants from AIDS Fonds, grants from Stichting AmsterdamDiner Foundation, grants from Gilead Sciences, grants from Janssen Pharmaceutica, grants from ViiV Healthcare, grants from ZonMW, grants from M.A.C AIDS Fund, during the conduct of the study; grants and other from Gilead Sciences, outside the submitted work. Dr. Reiss reports grants from AIDS Fonds, grants from Stichting AmsterdamDiner Foundation, grants from Gilead Sciences, grants from Janssen Pharmaceutica, grants from ViiV Healthcare, grants from ZonMW, grants from M.A.C AIDS Fund, during the conduct of the study; grants and other from Gilead Sciences, grants and other from ViiV Healthcare, grants and other from Merck, outside the submitted work. Dr. van Bergen reports grants from RIVM: national institute for public health and the environment, during the conduct of the study; and reports being a member of the board of the H-TEAM, a consortium of all actors involved in hiv-care and prevention in Amsterdam, with the ultimate goal to pursue the end of new hiv-infections in Amsterdam. The H- team is sponsored by a mix of organisations, including the Municipality, AIDS-funds, and several farmaceutical companies ( www.hteam.nl ). There are no personal fees or payment involved. Dr. Geerlings reports grants from Aidsfonds, during the conduct of the study. Funding Information: The H-TEAM initiative, of which this review is a project, is being supported by Aidsfonds (Grant No. 2013169 ), Stichting Amsterdam Dinner Foundation , Bristol-Myers Squibb International Corp . (study number: AI424–541 ), Gilead Sciences Europe Ltd (Grant No. PA-HIV-PREP-16-0024 ), Gilead Sciences (protocol numbers: CO-NL-276-4222 , CO-US-276-1712 ), Janssen Pharmaceutica (reference number: PHNL/JAN/0714/0005b/1912fde ), M.A.C AIDS Fund , ViiV Healthcare (PO numbers: 3000268822 , 3000747780 ) and ZonMw (Grant No. 522002003 ). This review is further funded by Aidsfonds (Grant No. P- 42702 ). The funders of the study had no role in the study design or execution. Publisher Copyright: © 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/5/1
Y1 - 2021/5/1
N2 - Background: Indicator condition (IC) guided testing for HIV is an effective way to identify undiagnosed people living with HIV, but studies suggest its implementation is lacking. This systematic review provides an overview of the adoption of IC-guided testing in Western countries. Methods: Seven ICs were selected: tuberculosis (TB), malignant lymphoma, hepatitis B, hepatitis C, cervical/vulvar carcinoma/intraepithelial neoplasia grade 2+ (CC/CIN2+, VC/VIN2+), and peripheral neuropathy (PN). Embase and Ovid MEDLINE were searched up to November 20th, 2020. Publications of all types, using data from ≥2009, reporting on HIV test ratios in patients ≥18 years in all settings in Western countries were eligible. HIV test ratios and positivity were reported per IC. A random effects-model for proportions was used to calculate estimated proportions (ES) with 95% CIs. This study was registered at PROSPERO, registration number CRD42020160243. Findings: Fifty-seven references, including 23 full-text articles and 34 other publications were included. Most (28/57) reported on HIV testing in TB. No reports on HIV testing in VC/VIN2+ or PN patients were eligible for inclusion. Large variation in HIV test ratios was observed between and within ICs, resulting from different testing approaches. Highest HIV test ratios (pooled ratio: 0·72, 95%CI 0·63–0·80) and positivity (0·05, 95% CI 0·03–0·06) were observed among TB patients, and lowest among CC/CIN2+ patients (pooled ES test ratio: 0·12, 95%CI 0·01–0·31, positivity: 0·00, 95%CI 0·00–0·00). Interpretation: IC-guided HIV testing is insufficiently implemented in Western countries. The large variation in test ratios provides insight into priority areas for implementing routine IC-guided HIV testing in the future. Funding: HIV Transmission Elimination in Amsterdam (H-TEAM) consortium and Aidsfonds (grant number P-42,702).
AB - Background: Indicator condition (IC) guided testing for HIV is an effective way to identify undiagnosed people living with HIV, but studies suggest its implementation is lacking. This systematic review provides an overview of the adoption of IC-guided testing in Western countries. Methods: Seven ICs were selected: tuberculosis (TB), malignant lymphoma, hepatitis B, hepatitis C, cervical/vulvar carcinoma/intraepithelial neoplasia grade 2+ (CC/CIN2+, VC/VIN2+), and peripheral neuropathy (PN). Embase and Ovid MEDLINE were searched up to November 20th, 2020. Publications of all types, using data from ≥2009, reporting on HIV test ratios in patients ≥18 years in all settings in Western countries were eligible. HIV test ratios and positivity were reported per IC. A random effects-model for proportions was used to calculate estimated proportions (ES) with 95% CIs. This study was registered at PROSPERO, registration number CRD42020160243. Findings: Fifty-seven references, including 23 full-text articles and 34 other publications were included. Most (28/57) reported on HIV testing in TB. No reports on HIV testing in VC/VIN2+ or PN patients were eligible for inclusion. Large variation in HIV test ratios was observed between and within ICs, resulting from different testing approaches. Highest HIV test ratios (pooled ratio: 0·72, 95%CI 0·63–0·80) and positivity (0·05, 95% CI 0·03–0·06) were observed among TB patients, and lowest among CC/CIN2+ patients (pooled ES test ratio: 0·12, 95%CI 0·01–0·31, positivity: 0·00, 95%CI 0·00–0·00). Interpretation: IC-guided HIV testing is insufficiently implemented in Western countries. The large variation in test ratios provides insight into priority areas for implementing routine IC-guided HIV testing in the future. Funding: HIV Transmission Elimination in Amsterdam (H-TEAM) consortium and Aidsfonds (grant number P-42,702).
UR - http://www.scopus.com/inward/record.url?scp=85105472856&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.eclinm.2021.100877
DO - https://doi.org/10.1016/j.eclinm.2021.100877
M3 - Article
C2 - 34027336
SN - 2589-5370
VL - 35
JO - EClinicalMedicine
JF - EClinicalMedicine
M1 - 100877
ER -